ARCHIVES

In Multi-Site Phase I Studies, No Investigator Sees All Toxicities

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | March 26, 2010

Download PDF Visit The Full Archive

Related Articles

CMS Advisors Express Low Confidence In Low-Dose CT Screening for Lung Cancer

May 9, 2014

FDA Approves Bexxar For Non-Hodgkin’s Lymphoma

June 27, 2003

Daily Humidification Improves Quality-of-Life in Phase III Trial

February 28, 2014

CCOP Reviewers Briefed On Program Objective, Criteria

January 7, 1983

Study Identifies Women Likely To Benefit From Therapy With Aromatase Inhibitors

November 24, 2006

Report on Carcinogens: Advisors Recommend Tobacco, UV Light, Tamoxifen, For Report

November 7, 1997